This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
Hemo Organic Q2 FY27: revenue jumps to Rs.142.90L, PAT negative, auditor flags issue
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Hemo Organic Q2 FY27 (Sept 30, 2026): Revenue surged to Rs.142.90L from Rs.0.20L YoY. Loss before tax was Rs.7.42L vs Rs.4.12L prior. H1 FY27 loss narrowed to Rs.6.89L from Rs.15.57L. Operating cash flow was deeply negative at Rs.minus 182.72L for H1. Auditor issued a qualified opinion citing missing balance confirmations for trade receivables and payables. Company converted 34 lakh warrants into equity, doubling share capital to Rs.686.59L.
Revenue growth is positive, but losses continue, cash burn is high, and auditor-qualified review raises concerns. Net worth still negative.
The company's XBRL figures for this quarter look filed in the wrong unit: revenue reads ₹1.43 Cr against ₹0.00 Cr a year ago, about 14,290× larger. A move that size is almost always a wrong unit, not a business, so nothing is computed from these figures and no number-based tags are set; the read above is the AI's, from the document.